Dacarbazine - Pharmacology
Research News and Information

Sunday, November 22, 2009

Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity.

29 Sep 2009 Low-dose hyper-radiosensitivity (HRS) is the phenomenon whereby cells exposed to radiation doses of less than approximately 0.5 Gy exhibit increased cell killing relative to that predicted from back-extrapolating high-dose survival data using a ... Read more...

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

30 Jul 2009 INO-1001 is a PARP-1 inhibitor that interrupts the repair process of N-methylpurines generated by temozolomide. We evaluated the pharmacokinetics of INO-1001 and determined its safety when used with temozolomide at 200 mg/m(2)/day x 5 days every 4 ... Read more...

IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.

30 Jul 2009 The consistently observed inverse relationship of allergic conditions with glioma risk and our previous demonstration that immunoglobulin E (IgE) levels also were lower in glioma patients than controls suggest that atopic allergy may be related to a ... Read more...

Latest indexed articles for 'Dacarbazine - Pharmacology'

These are the very latest articles for this heading:

• Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity. 29 Sep 2009
• A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. 30 Jul 2009
• IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. 30 Jul 2009
• The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. 27 Jul 2009
• Comment re: Temozolomide preferentially depletes cancer stem cells. 19 Jul 2009
• DNA ligase IV as a new molecular target for temozolomide. 13 Jul 2009
• A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. 10 Jul 2009
• MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. 5 Jul 2009
• FEN1 is overexpressed in testis, lung and brain tumors. 29 Jun 2009
• The safety of temozolomide in the treatment of malignancies. 29 Jun 2009
• Temozolomide in malignant gliomas: current use and future targets. 17 Jun 2009
• In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. 6 Jun 2009
• Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. 3 Jun 2009
• Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines. 30 May 2009
• Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. 30 May 2009
• Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. 17 May 2009
• Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation. 13 May 2009
• Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. 10 May 2009
• Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies. 5 May 2009
• Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition. 9 Apr 2009

See a longer list of these articles.

Technical information about 'Dacarbazine'

Definition: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

Chemical name: 1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-

Registry Number: 4342-03-4

Descriptor UI: D003606

Alternative terms: Dacarbazine; Decarbazine; DIC; Dimethyl Triazeno Imidazole Carboxamide; DTIC; ICDT; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; Dimethyl Imidazole Carboxamide; Carboxamide, Dimethyl Imidazole; Imidazole Carboxamide, Dimethyl; NSC-45388; NSC 45388; NSC45388; DTIC-Dome; DTIC Dome; DTICDome; Biocarbazine; Deticene;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antineoplastic Agents, Alkylating;

Tree Number: D02.925.200; D03.383.129.308.240;

History Note: 80(75)